JP2007511474A - 神経変性障害に関与する遺伝子 - Google Patents

神経変性障害に関与する遺伝子 Download PDF

Info

Publication number
JP2007511474A
JP2007511474A JP2006536050A JP2006536050A JP2007511474A JP 2007511474 A JP2007511474 A JP 2007511474A JP 2006536050 A JP2006536050 A JP 2006536050A JP 2006536050 A JP2006536050 A JP 2006536050A JP 2007511474 A JP2007511474 A JP 2007511474A
Authority
JP
Japan
Prior art keywords
protein
modulator
subject
gene
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006536050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511474A5 (https=
Inventor
ダリア・コーエン
ウヴェ・ヨッヘン・デングラー
ダニー・ガーザ
アンジュ・エヌ・ケルカール
メアリー・コンソラキ
ソン・ホジュン
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2007511474A publication Critical patent/JP2007511474A/ja
Publication of JP2007511474A5 publication Critical patent/JP2007511474A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006536050A 2003-10-22 2004-10-21 神経変性障害に関与する遺伝子 Pending JP2007511474A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51324103P 2003-10-22 2003-10-22
PCT/EP2004/011926 WO2005039635A2 (en) 2003-10-22 2004-10-21 Genes involved in neurodegenerative disorders

Publications (2)

Publication Number Publication Date
JP2007511474A true JP2007511474A (ja) 2007-05-10
JP2007511474A5 JP2007511474A5 (https=) 2007-12-06

Family

ID=34520083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536050A Pending JP2007511474A (ja) 2003-10-22 2004-10-21 神経変性障害に関与する遺伝子

Country Status (4)

Country Link
US (1) US20090016963A1 (https=)
EP (1) EP1678326A2 (https=)
JP (1) JP2007511474A (https=)
WO (1) WO2005039635A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1859274A2 (en) * 2005-03-07 2007-11-28 Novartis AG Genes involved in neurodegenerative conditions
JP4191189B2 (ja) * 2005-12-08 2008-12-03 康生 梅津 がん関連遺伝子活性化能を有するペプチド
ES2310434B1 (es) * 2006-01-19 2009-11-12 Consejo Superior Investig. Cientificas Un pmto de identificacion de un proceso de fibrosis renal, pmto de identificacion de compuestos inhibidores, uso de los compuestos inhibidores de la expresion del gen del factor de transcripcion snail en la elaboracion de composiciones farmaceuticas, dichas composiciones.....
JP5451376B2 (ja) * 2007-03-15 2014-03-26 株式会社リバース・プロテオミクス研究所 血球系に特異的あるいは破骨細胞分化に特異的なバイオマーカー
US8153764B2 (en) 2007-03-15 2012-04-10 Reverse Proteomics Research Institute Co., Ltd. Biomarker specific to brain/nerve or specific to neuronal differentiation
EP3915552A1 (en) * 2015-06-01 2021-12-01 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
CN109298186A (zh) * 2018-09-29 2019-02-01 安徽科技学院 一种基于碳纳米管和三螺旋分子开关的试纸条生物传感器及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026820A2 (en) * 2000-09-29 2002-04-04 Novartis Ag Immunomodulatory protein derived from the yaba monkey tumor virus
WO2003061681A2 (en) * 2002-01-25 2003-07-31 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis and organelle metabolism

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7129700A (en) * 1999-09-10 2001-04-10 Corixa Corporation Ovarian tumor sequences and methods of use therefor
WO2002057496A2 (en) * 2001-01-18 2002-07-25 Socratech L.L.C. Gene expression profiling of endothelium in alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026820A2 (en) * 2000-09-29 2002-04-04 Novartis Ag Immunomodulatory protein derived from the yaba monkey tumor virus
WO2003061681A2 (en) * 2002-01-25 2003-07-31 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis and organelle metabolism

Also Published As

Publication number Publication date
EP1678326A2 (en) 2006-07-12
US20090016963A1 (en) 2009-01-15
WO2005039635A2 (en) 2005-05-06
WO2005039635A3 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
Burke et al. Dispatched, a novel sterol-sensing domain protein dedicated to the release of cholesterol-modified hedgehog from signaling cells
JP2000517185A (ja) 新規なメタロプロテアーゼファミリーｋｕｚ
Plank et al. Drosophila melanogaster topoisomerase IIIα preferentially relaxes a positively or negatively supercoiled bubble substrate and is essential during development
US6900367B2 (en) Transgenic Drosophila melanogaster expressing a β42 in the eye
US20080152644A1 (en) Genes Involved in Neurodegenerative Conditions
JP2002510490A (ja) Ｌｙｓｔタンパク質複合体およびｌｙｓｔ相互作用タンパク質
JP2007511474A (ja) 神経変性障害に関与する遺伝子
Huang et al. A zinc metalloprotease nas-33 is required for molting and survival in parasitic nematode Haemonchus contortus
US20050085436A1 (en) Method to treat conditions associated with insulin signalling dysregulation
JP2002511747A (ja) 耐糖能障害疾患に対する治療および診断ツール
AU2001262988B2 (en) Presenilin enhancers
US20060179497A1 (en) Methods to treat conditions associated with insulin signaling dysregulation
WO2001096371A2 (en) Adipose-related gene
EP1207200B1 (en) High affinity choline transporter
GB2411403A (en) Transgenic animals with altered NCS-1 expression
US20030165897A1 (en) Dispatched polypeptides
JP4515266B2 (ja) Ｂ７−２分子またはｍｈｃクラスｉｉ分子等の抗原提示関連分子の細胞表面における発現を負に制御する哺乳類由来の新規タンパク質とその利用
JP4375960B2 (ja) 生体代謝の修飾
EP1728424A2 (en) Method to treat conditions associated with insulin signaling dysregulation
EP1571903A1 (en) Method to treat conditions associated with insulin signaling dysregulation
WO2004108079A2 (en) Parkin-interacting proteins
Ruan A Study of Genes in Spermatogenesis: The Potential Functions of tGAP and Oaz3
Liu Determination of the essential functions of a conserved cyclin, Cyclin Y, in Drosophila
JP2006527593A (ja) 代謝性疾患の予防及び／又は治療のための化合物を開発するために有用なアルコールデヒドロゲナーゼ配列

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110712